Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 4:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 167 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Actinic Keratoses Clear all
Recruiting Phase 3 Interventional

A Pilot Clinical Trial Comparing Topical Fluorouracil to Fluorouracil Plus Calcipotriene Field Treatments in Patients With Multiple Actinic Keratoses

NCT06851507
View directory record Official record
Conditions
Multiple Actinic Keratoses
Interventions
Fluorouracil 5-FU, Fluorouracil/Calcipotriene
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 12, 2026, 4:39 PM EDT
Completed Phase 2 Interventional Results available

Perimenstrual Acne With Clindamycin Phosphate and Benzoyl Peroxide

NCT03122457
View directory record Official record
Conditions
Actinic Keratosis
Interventions
lidamycin phosphate and benzoyl peroxide 1.2%/3.75% combination
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 4, 2020 · Synced Oct 12, 2026, 4:39 PM EDT
Completed Phase 1 Interventional

Ph 1, Single-Center, Safety, Tolerability & Pharmacokinetic Study of KX2 391 Ointment in Subj. w Actinic Keratosis

NCT02337205
View directory record Official record
Conditions
Actinic Keratosis
Interventions
KX2-391 Ointment
Drug
Lead sponsor
Athenex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2018 · Synced Oct 12, 2026, 4:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Photoallergic Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers

NCT00850681
View directory record Official record
Conditions
Actinic Keratosis
Interventions
PEP005 (ingenol mebutate) Gel
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 9, 2015 · Synced Oct 12, 2026, 4:39 PM EDT
Completed Phase 2 Interventional Results available

Levulan PDT Versus Vehicle for Extremity Actinic Keratoses (AK)

NCT01458587
View directory record Official record
Conditions
Keratosis, Actinic
Interventions
Aminolevulinic Acid PDT (ALA), Vehicle PDT (VEH)
Drug
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
San Diego, California • Orange Park, Florida • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 14, 2013 · Synced Oct 12, 2026, 4:39 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis

NCT02120456
View directory record Official record
Conditions
Actinic Keratosis
Interventions
LEO 43204, Placebo
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
13
States / cities
Phoenix, Arizona • Lomita, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 12, 2026, 4:39 PM EDT
Completed Phase 3 Interventional Results available

A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations

NCT00942604
View directory record Official record
Conditions
Actinic Keratoses
Interventions
PEP005 (ingenol mebutate) Gel, Vehicle gel
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
17
States / cities
Hot Springs, Arizona • San Diego, California • Alpharetta, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 12, 2026, 4:39 PM EDT
Completed Phase 1 Interventional

Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides

NCT00103246
View directory record Official record
Conditions
Lymphoma, Non-melanomatous Skin Cancer, Precancerous Condition
Interventions
silicon phthalocyanine 4
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Oct 12, 2026, 4:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Study to Evaluate the Sensitizing Potential of LEO 43204 Gel

NCT02650505
View directory record Official record
Conditions
Actinic Keratosis
Interventions
LEO 43204, LEO 43204 Vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
233 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 12, 2026, 4:39 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Participants With Actinic Keratoses

NCT02120898
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Imiquimod, Zyclara®, Vehicle Cream
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
27
States / cities
Birmingham, Alabama • Fremont, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Oct 12, 2026, 4:39 PM EDT
Completed Phase 2 Interventional Results available

Maximal Use Systemic Exposure (MUSE) Study of Levulan Kerastick

NCT02281136
View directory record Official record
Conditions
Keratosis, Actinic
Interventions
Aminolevulinic Acid (ALA), BLU-U
Drug · Device
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
San Diego, California • Carmel, Indiana • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Oct 12, 2026, 4:39 PM EDT
Completed Phase 2 Interventional Results available

Microneedle Lesion Preparation Prior to Aminolevulinic Acid Photodynamic Therapy (ALA-PDT) for AK on Face

NCT02632110
View directory record Official record
Conditions
Actinic Keratosis
Interventions
ALA, Topical Solution Vehicle, IBL 10 mW, Microneedle lesion preparation, IBL 20 mW
Drug · Device · Procedure
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
8
States / cities
San Diego, California • Brandon, Florida • Arlington Heights, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 12, 2026, 4:39 PM EDT
Recruiting Phase 3 Interventional

Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp

NCT07144345
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%, Vehicle containing excipients only (VEH) without active ingredient, Blue Light Photodynamic Therapy Illuminator device, BLU-U® model 4170E
Drug · Other · Device
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
Fremont, California • Aventura, Florida • Rolling Meadows, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 12, 2026, 4:39 PM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

PDT vs Peels for Treatment of Actinic Keratoses

NCT04429308
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Photodynamic Therapy, Chemical Peels
Procedure · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 12, 2026, 4:39 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities

NCT02137785
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Aminolevulinic Acid (ALA), Topical Solution Vehicle, Blue Light Photodynamic Therapy Illuminator (BLU-U)
Drug · Device
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
13
States / cities
Fremont, California • San Diego, California • Aventura, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2015 · Synced Oct 12, 2026, 4:39 PM EDT
Completed Phase 1 Interventional

Biological Effects of LEO 43204 in Actinic Keratosis

NCT02600598
View directory record Official record
Conditions
Actinic Keratosis
Interventions
LEO 43204 Gel, 0.037%
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Quincy, Massachusetts • Smithtown, New York
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 12, 2026, 4:39 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Celecoxib in Preventing Skin Cancer in Patients With Actinic Keratoses

NCT00027976
View directory record Official record
Conditions
Precancerous Condition
Interventions
celecoxib, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
7
States / cities
Birmingham, Alabama • Irvine, California • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2013 · Synced Oct 12, 2026, 4:39 PM EDT
Completed No phase listed Observational

A Long Term Follow up Study of Patients Who Have Completed the PEP005-020 Study

NCT00952783
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Lesion count
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
8
States / cities
Orange Park, Florida • Newnan, Georgia • Snellville, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2015 · Synced Oct 12, 2026, 4:39 PM EDT
Completed No phase listed Observational

A Long Term Follow up Study of Patients Who Have Complete Clearance of Their Actinic Keratosis (AK) Lesions at the Day 57 Visit in the PEP005-028 Study

NCT00989313
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Lesion count
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
17
States / cities
Hot Springs, Arizona • San Diego, California • Alpharetta, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2015 · Synced Oct 12, 2026, 4:39 PM EDT
Completed Phase 3 Interventional

A Multi-center Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on Non-head Locations (Trunk and Extremities)

NCT00917306
View directory record Official record
Conditions
Actinic Keratosis
Interventions
PEP005 Gel
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
8
States / cities
Orange Park, Florida • Newnan, Georgia • Snellville, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 12, 2026, 4:39 PM EDT
Recruiting Not applicable Interventional

The Preventive Role of Fractionated Laser Resurfacing Against Actinic Neoplasia in an At-Risk Geriatric Population

NCT06428721
View directory record Official record
Conditions
Actinic Keratoses, Aging, Non-Melanoma Skin Cancer
Interventions
Fractionated Laser Resurfacing
Device
Lead sponsor
Wright State University
Other
Eligibility
60 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
Fairborn, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 12, 2026, 4:39 PM EDT
Terminated Phase 2 Interventional

ALA-PDT Versus Vehicle PDT for Treatment of AK and Reduction of New NMSC in Solid Organ Transplant Recipients

NCT00865878
View directory record Official record
Conditions
Actinic Keratoses, Skin Neoplasms
Interventions
Aminolevulinic Acid, Vehicle
Drug · Other
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
7
States / cities
Irvine, California • San Francisco, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2011 · Synced Oct 12, 2026, 4:39 PM EDT
Completed Early Phase 1 Interventional

Actinic Keratosis Study

NCT02019355
View directory record Official record
Conditions
Actinic Keratosis
Interventions
5-fluorouracil 5% cream, Calcipotriol 0.005% ointment, Vaseline
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Oct 12, 2026, 4:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Efudex Treatment on Photoaged Skin

NCT00121511
View directory record Official record
Conditions
Photo-aging, Keratosis
Interventions
Efudex (5-fluorouracil)
Drug
Lead sponsor
University of Michigan
Other
Eligibility
50 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Oct 12, 2026, 4:39 PM EDT